Business
Helix BioPharma Corp. Closes Private Placement
RICHMOND HILL, ON / ACCESSWIRE / December 30, 2020 / Helix BioPharma Corp. ( TSX:HBP ) ("Hel...
About this update from Helix Biopharma Corp.
[{"type":"text","content":"Helix BioPharma Corp. Closes Private PlacementRICHMOND HILL, ON / ACCESSWIRE / December 30, 2020 / Helix BioPharma Corp. (TSX:HBP) (\"Helix\" or the \"Company\"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced it has closed a private placement financing for gross proceeds of $3,000,000.The terms of the placement are for the purchase of units at $0.50 per unit. Each unit is comprised of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to purchase one common share at an exercise price of $0.70 and have an expiry of five years from the date of issuance. Helix intends to use the net proceeds of the private placement for working capital and research and development activities.ACM Alpha Consulting Management AG provided financial advisory services to Helix in connection with the private placement.About Helix BioPharma Corp.Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. Helix is a biopharmaceutical company developing unique therapies in the field of immuno-oncology, for the prevention and treatment of cancer, based on its proprietary technology platform DOS47. Helix is currently listed on the TSX under the symbol \"HBP\". For more information: https://www.helixbiopharma.comInvestor RelationsHelix BioPharma Corp.9120 Leslie Street, Suite 205Richmond Hill, Ontario, L4B 3J9Phone: + 1 (905) [email protected] Bronze, LLCMr. Pascal NigenPhone: + 1 (917) [email protected] StatementsThis news release may contain forward-looking statements with respect to Helix, its operations, strategy, financial performance and condition, including its activities relating to its drug development program, any anticipated timelines for the commencement or completion of certain activities such as raising sufficient capital, merger and acquisition activity, listing on a U.S. exchange and other information in future periods. These statements generally can be identified by use of forward-looking words such as \"may\", \"will\", \"expect\", \"estimate\", \"anticipate\", \"intends\", \"believe\" or \"continue\" or the negative thereof or similar variations. The actual results and performan...